BioSpace News Archive

Inspyr Therapeutics, Inc. (OTC/PINK:NSPX), announces that it has acquired a novel immuno-oncology delivery technology targeting adenosine receptor antagonists for the treatment of cancer.

Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2020 financial results on Tuesday, October 27, 2020 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the company’s financial performance. The conference call will begin at 9 a.m. Eastern time . Investor

Spruce Biosciences, Inc ., a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. The shares are expected to begin trading on the Na

Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, October 29, 2020, the Company will release financial results for the second quarter of fiscal 2021. The Company will host a conference call to discuss the results on Thursday, October 29, 2020 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call. To listen to

The National Institute on Aging (NIA) has awarded Cayman Chemical with a Phase II Small Business Innovation Research (SBIR) grant to develop an assay platform and novel antibodies to support the treatment, prevention, and early diagnosis of Alzheimer’s disease and other tauopathies.

Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI), a manufacturer of high quality cannabinoid-based formulations and products, today announced its results for the first quarter ended June 30, 2020 and provided an update on recent corporate developments.

Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease, today announced the pricing of its upsized initial public offering of 11,882,352 shares of common stock at a public offering price of $17.00 per share. The gross proceeds to Shattuck from

- Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, today announced the pricing of its initial public offering of 13,157,895 shares of its common stock at a price to the public of $19.00 per share. The gross proceeds to Kronos Bio from the offering, before deduct

Cipher Pharmaceuticals Inc. announced the voting results for the election of directors at its Annual Meeting of Shareholders held earlier.

With a $500,000 Research Grant from Alliance for Cancer Gene Therapy (ACGT), Sidi Chen, PhD, assistant professor in the Department of Genetics and Systems Biology Institute at Yale School of Medicine and member of Yale Cancer Center, will advance a versatile and highly scalable strategy he’s been developing and calling MAEGI -- Multiplexed Activation of Endogenous Genes as an Immunotherapy.